Welcome to our newsroom – Here you will find news and other resources to help keep you up to date on our progress.
December 2023
VJHemeOnc – ASH 2023 | Investigating AB1 as a tool to upregulate fetal hemoglobin in SCD: preclinical and clinical findings
In this video interview, Nirmish Shah, MD of Duke University discusses the preclinical and clinical findings regarding the use of AB1, a DNMT1 protein depleter, as an agent to upregulate fetal hemoglobin in sickle cell disease (SCD). This interview took place at the 65th ASH Annual Meeting and Exposition, held December 2023 in San Diego, CA.
Consultant360 – Use of AB1 to Upregulate Fetal Hemoglobin in Patients With Sickle Cell Disease
In this podcast, Nirmish Shah, MD, discusses an overview, the results, and the preclinical and clinical impact of the study titled “Preclinical and Clinical Use of AB1, a DNMT1 Protein Depleter, to Upregulate Fetal Hemoglobin in Townes Sickle Cell Disease (SCD) Mice and Patients with SCD.” Dr Shah also presented on this topic at the American Society of Hematology’s 2023 annual meeting held December 2023 in San Diego, CA.